SCHEDULE 13G/A: Janus Henderson Group Discloses 9.9% Passive Stake in Tenax Therapeutics
Beneficial Ownership Disclosure
Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a passive beneficial ownership of 9.9% in Tenax Therapeutics, Inc. through an amended Schedule 13G filing.
Summary
- Janus Henderson Group PLC and Janus Henderson Biotech Innovation Master Fund Ltd collectively hold 396,642 shares of Tenax Therapeutics, Inc. common stock.
- This represents a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc.
- The filing is an Amendment No. 3 to a previously filed Schedule 13G, indicating an update to their ownership disclosure.
- The reporting persons, Janus Henderson Group PLC (based in Jersey) and Janus Henderson Biotech Innovation Master Fund Ltd (based in Massachusetts), have shared voting and dispositive power over all 396,642 shares.
- The securities were acquired and are held for investment purposes and not with the intent of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory disclosure of a passive investment stake and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
No forward-looking statements or guidance regarding Tenax Therapeutics, Inc. were provided in this beneficial ownership disclosure.
Industry Context
This filing is a routine disclosure by an institutional investment manager, Janus Henderson Group, regarding its passive stake in a biotechnology company, Tenax Therapeutics. It reflects a standard investment position rather than a strategic industry move or competitive action.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of Power of Attorney execution by Janus Henderson Group plc. |
| 2025-03-31 | Date of event which required the filing of this statement (end of reporting period). |
| 2025-05-14 | Signature date of the Schedule 13G Amendment No. 3 filing. |
Keywords
Tenax Therapeutics, Janus Henderson Group, Janus Henderson Biotech Innovation Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotech, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.